Register for real-time alerts, custom portfolio, and market movers
Cellceutix (OTC:CTIX) is a clinical stage biotechnology company focused on discovering small molecule drugs for hard to treat diseases, including cancer, psoriasis, autism, and inflammatory disease.
The main drug for Cellceutix is Kevetrin. Thus far, Kevetrin has shown a great deal of potential in treating advanced solid tumors. Clinical trials have already started at Harvard University’s Dana-Farber Cancer Institute.
In the pre-clinical trials, Kevetrin was shown to be effective against several forms of cancer including advanced tumors, lung, breast, colon, prostate, leukemia, and brain tumors. Kevetrin is proving to be effective because it seems to be able to activate the p53 gene, also known as the “guardian angel gene.” P53 activates proteins that are necessary in order to repair DNA. The p53 gene also helps to maintain cellular and genetic stability by inducing programmed cell death.
The company also recently inked a deal with Aspire Capital to provide $10 million in financing under very favorable terms. This helps to alleviate concerns about dilution in the near-term.
Investors should expect a lot of updates and announcements from the company this year and I feel that investors will all be rewarded handsomely.
** Disclaimer: I am long Cellceutix **
